Beta Drugs Ltd

Beta Drugs Ltd Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Beta Drugs Ltd

₹ 2,478 1.60%
21 Jul - close price
betadrugslimited.com NSE: BETA
About

Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]

Key Points

Market Position
The company is ranked among the top 10 oncology companies, and many of its key products are ranked among the top 5 in their respective categories. [1]

Website NSE
  • Market Cap ₹ 2,512 Cr.
  • Current Price ₹ 2,478
  • High / Low ₹ 2,674 / 990
  • Stock P/E 157
  • Book Value ₹ 148
  • Dividend Yield 0.00 %
  • ROCE 11.2 %
  • ROE 10.3 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company's median sales growth is 21.5% of last 10 years

Cons

  • Stock is trading at 16.8 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
48.27 53.74 66.32 54.48 50.28 54.35 55.83
42.55 48.49 58.80 49.75 43.74 44.60 45.68
Operating Profit 5.72 5.25 7.52 4.73 6.54 9.75 10.15
OPM % 11.85% 9.77% 11.34% 8.68% 13.01% 17.94% 18.18%
-1.47 1.71 2.97 2.74 2.51 2.92 1.87
Interest 1.33 2.81 2.79 2.97 3.17 2.87 1.60
Depreciation 1.92 2.14 2.04 2.38 2.51 2.74 2.49
Profit before tax 1.00 2.01 5.66 2.12 3.37 7.06 7.93
Tax % 25.00% 30.85% 25.09% 28.77% 3.56% 24.50% 25.22%
0.75 1.39 4.23 1.51 3.25 5.33 5.93
EPS in Rs 0.74 1.38 4.19 1.50 3.21 5.26 5.69
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
0 26 42 51 58 65 79 125 158 197 220 225 215
0 23 34 41 48 54 64 99 126 164 189 197 184
Operating Profit 0 3 7 9 10 12 15 25 31 34 31 29 31
OPM % 0% 11% 17% 19% 18% 18% 19% 20% 20% 17% 14% 13% 14%
0 0 0 0 0 0 1 1 1 2 2 11 10
Interest 0 1 1 1 1 1 1 0 1 1 5 12 11
Depreciation 0 1 1 2 2 3 5 5 6 5 7 10 10
Profit before tax -0 1 5 7 7 9 10 20 25 29 21 18 20
Tax % 0% 0% 19% 1% -3% 21% 29% 29% 25% 26% 26% 21%
-0 1 4 7 8 7 7 14 19 22 15 14 16
EPS in Rs -1.00 10.27 38.82 7.43 8.47 7.03 6.91 14.11 18.63 21.72 15.29 14.14 15.66
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 24%
5 Years: 23%
3 Years: 13%
TTM: 2%
Compounded Profit Growth
10 Years: 29%
5 Years: 15%
3 Years: -9%
TTM: -24%
Stock Price CAGR
10 Years: %
5 Years: 47%
3 Years: 53%
1 Year: 48%
Return on Equity
10 Years: 17%
5 Years: 17%
3 Years: 15%
Last Year: 10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 1 1 1 9 9 10 10 10 10 10 10 10
Reserves 0 1 5 24 32 47 54 68 87 106 119 139
5 8 8 8 8 9 5 7 6 6 128 130
2 5 9 9 16 17 18 27 32 49 60 55
Total Liabilities 8 15 23 50 65 82 86 111 134 170 317 335
1 7 8 13 12 32 28 34 35 36 53 76
CWIP 6 0 0 1 15 0 2 0 0 0 0 0
Investments 0 0 0 0 2 6 7 7 7 6 6 6
2 8 15 35 36 44 50 70 93 128 257 254
Total Assets 8 15 23 50 65 82 86 111 134 170 317 335

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1 -0 5 17 8 6 12 19 10 21 18 19
-6 -2 -2 -11 -16 -14 -3 -13 -6 -11 -21 -31
4 3 -3 5 -1 9 -4 1 -2 -1 118 -11
Net Cash Flow 0 0 0 12 -9 1 4 7 2 9 115 -24
Free Cash Flow -4 -3 3 9 -7 -1 8 9 3 15 -6 -13
CFO/OP -4% 65% 181% 75% 52% 76% 74% 33% 63% 57% 67%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 112 61 92 104 109 117 96 92 101 93 81 87
Inventory Days 3,115 69 37 38 76 64 65 44 60 71 84 94
Days Payable 5,256 97 108 82 121 97 111 101 102 116 124 132
Cash Conversion Cycle -2,029 33 21 60 64 84 49 34 59 48 41 49
Working Capital Days -758 -19 17 50 62 65 81 63 83 72 68 74
ROCE % -3% 22% 49% 29% 18% 17% 16% 27% 28% 27% 16% 11%

Insights

In beta
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Number of CDMO Partners
count

Log in to view insights

Please log in to see hidden values.

Login
Number of Countries Exported To
count
Number of Oncology Products/SKUs
count
API Manufactured In-house (% of formulation API)
%
Cumulative Active Dossier Registrations (Exports)
count
Derma Field Force PCPM
INR per TM per month
Lyophilized Injection Capacity Utilization
%
Oncology Brands > INR 5 Crores
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 64.90% 64.63% 59.10%
0.32% 0.32% 0.32% 0.90% 1.16% 1.15% 0.90% 0.90% 0.90% 1.14% 1.16% 1.02%
0.02% 0.02% 0.06% 0.12% 0.16% 0.17% 0.17% 0.26% 0.29% 1.90% 2.15% 6.23%
32.93% 32.92% 32.87% 32.25% 31.95% 31.95% 32.20% 32.11% 32.07% 32.07% 32.06% 33.65%
No. of Shareholders 1,7221,9282,1162,3232,5672,8823,0543,1393,1843,6944,7367,359

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls